{"brief_title": "ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer", "brief_summary": "This is a non-randomized, phase 1, study with the primary objective of determining the toxicities and establishing the maximum tolerated dose of ALIMTA when administered as a 10 minute infusion every 21 days with folic acid or multi-vitamin supplementation therapy in lightly or heavily pre-treated patients with locally advanced or metastatic cancer.", "condition": "Cancer", "intervention_type": "Drug", "intervention_name": "multi-vitamins", "criteria": "Inclusion Criteria: - Histologic or cytologic diagnosis of metastatic or locally advanced cancer - Prior chemotherapy is allowed - Adequate bone marrow, liver and kidney function Exclusion Criteria: - Prior treatment with ALIMTA - Brain metastasis - Pregnancy or breast feeding", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00034463.xml"}